{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T13:07:04Z","timestamp":1775653624176,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004160","name":"Mazandaran University of Medical Sciences","doi-asserted-by":"publisher","award":["17690"],"award-info":[{"award-number":["17690"]}],"id":[{"id":"10.13039\/501100004160","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03259-w","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T13:23:54Z","timestamp":1770297834000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted delivery of venetoclax-encapsulated human heavy chain ferritin nanoparticles in acute myeloid leukemia"],"prefix":"10.1007","volume":"43","author":[{"given":"Mohadeseh","family":"Khodaverdian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misagh","family":"Rajabinejad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Valadan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majid","family":"Saeedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Negarandeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadi","family":"Hossein-Nataj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramin","family":"Shekarriz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Asgarian-Omran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"3259_CR1","doi-asserted-by":"publisher","first-page":"16010","DOI":"10.1038\/nrdp.2016.10","volume":"2","author":"A Khwaja","year":"2016","unstructured":"Khwaja A, Bjorkholm M, Gale RE, Levine RL, Jordan CT, Ehninger G, et al. Acute myeloid leukaemia. Nat Reviews Disease Primers. 2016;2:16010.","journal-title":"Nat Reviews Disease Primers"},{"issue":"1","key":"3259_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41408-023-00954-z","volume":"14","author":"JJ Lim","year":"2024","unstructured":"Lim JJ, Othus M, Shaw CM, Russell K, Halpern AB, Appelbaum JS, et al. Time independent factors that predict relapse in adults with acute myeloid leukemia. Blood Cancer J. 2024;14(1):5.","journal-title":"Blood Cancer J"},{"issue":"1","key":"3259_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13045-023-01424-6","volume":"16","author":"RS Bhansali","year":"2023","unstructured":"Bhansali RS, Pratz KW, Lai C. Recent advances in targeted therapies in acute myeloid leukemia. J Hematol Oncol. 2023;16(1):29.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"3259_CR4","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12964-024-01607-9","volume":"22","author":"A Doostmohammadi","year":"2024","unstructured":"Doostmohammadi A, Jooya H, Ghorbanian K, Gohari S, Dadashpour M. Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents. Cell Communication Signal. 2024;22(1):228.","journal-title":"Cell Communication Signal"},{"issue":"10","key":"3259_CR5","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1182\/blood-2018-03-828269","volume":"132","author":"M Konopleva","year":"2018","unstructured":"Konopleva M, Letai A. BCL-2 Inhibition in AML: an unexpected bonus? Blood. 2018;132(10):1007\u201312.","journal-title":"Blood"},{"key":"3259_CR6","doi-asserted-by":"publisher","first-page":"584974","DOI":"10.3389\/fonc.2020.584974","volume":"10","author":"Y Wei","year":"2020","unstructured":"Wei Y, Cao Y, Sun R, Cheng L, Xiong X, Jin X, et al. Targeting Bcl-2 proteins in acute myeloid leukemia. Front Oncol. 2020;10:584974.","journal-title":"Front Oncol"},{"key":"3259_CR7","first-page":"2628","volume":"130","author":"CD DiNardo","year":"2017","unstructured":"DiNardo CD, Pollyea DA, Jonas BA, Konopleva M, Pullarkat V, Wei A, et al. Updated safety and efficacy of venetoclax with decitabine or Azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2017;130:2628.","journal-title":"Blood"},{"issue":"7","key":"3259_CR8","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617\u201329.","journal-title":"N Engl J Med"},{"issue":"1","key":"3259_CR9","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1182\/hematology.2020000120","volume":"2020","author":"K Fischer","year":"2020","unstructured":"Fischer K, Al-Sawaf O, Hallek M. Preventing and monitoring for tumor Lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia. Hematol Am Soc Hematol Educ Program. 2020;2020(1):357\u201362.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"1","key":"3259_CR10","first-page":"2198098","volume":"28","author":"Y Du","year":"2023","unstructured":"Du Y, Li C, Yan J. The efficacy and safety of venetoclax and Azacytidine combination treatment in patients with acute myeloid leukemia and myelodysplastic syndrome: systematic review and meta-analysis. Hematol (Amsterdam Netherlands). 2023;28(1):2198098.","journal-title":"Hematol (Amsterdam Netherlands)"},{"issue":"2","key":"3259_CR11","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","volume":"19","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, et al. Safety and preliminary efficacy of venetoclax with decitabine or Azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(2):216\u201328.","journal-title":"Lancet Oncol"},{"issue":"5","key":"3259_CR12","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1182\/bloodadvances.2020003734","volume":"5","author":"M Stahl","year":"2021","unstructured":"Stahl M, Menghrajani K, Derkach A, Chan A, Xiao W, Glass J, et al. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML. Blood Adv. 2021;5(5):1552\u201364.","journal-title":"Blood Adv"},{"issue":"6","key":"3259_CR13","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41419-024-06810-7","volume":"15","author":"GO Nwosu","year":"2024","unstructured":"Nwosu GO, Ross DM, Powell JA, Pitson SM. Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia. Cell Death Dis. 2024;15(6):413.","journal-title":"Cell Death Dis"},{"key":"3259_CR14","doi-asserted-by":"publisher","first-page":"104623","DOI":"10.1016\/j.jddst.2023.104623","volume":"86","author":"M Assefi","year":"2023","unstructured":"Assefi M, Ataeinaeini M, Nazari A, Gholipour A, Vertiz-Osores JJ, Melody Calla-V\u00e1squez K, et al. A state-of-the-art review on solid lipid nanoparticles as a nanovaccines delivery system. J Drug Deliv Sci Technol. 2023;86:104623.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3259_CR15","doi-asserted-by":"publisher","first-page":"119947","DOI":"10.1016\/j.lfs.2021.119947","volume":"285","author":"H Serati-Nouri","year":"2021","unstructured":"Serati-Nouri H, Rasoulpoor S, Pourpirali R, Sadeghi-Soureh S, Esmaeilizadeh N, Dadashpour M, et al. In vitro expansion of human adipose-derived stem cells with delayed senescence through dual stage release of Curcumin from mesoporous silica nanoparticles\/electrospun nanofibers. Life Sci. 2021;285:119947.","journal-title":"Life Sci"},{"key":"3259_CR16","doi-asserted-by":"publisher","first-page":"123880","DOI":"10.1016\/j.ijpharm.2024.123880","volume":"653","author":"S Kamalipooya","year":"2024","unstructured":"Kamalipooya S, Fahimirad S, Abtahi H, Golmohammadi M, Satari M, Dadashpour M, et al. Diabetic wound healing function of PCL\/cellulose acetate nanofiber engineered with chitosan\/cerium oxide nanoparticles. Int J Pharm. 2024;653:123880.","journal-title":"Int J Pharm"},{"issue":"3","key":"3259_CR17","doi-asserted-by":"publisher","first-page":"919","DOI":"10.31557\/APJCP.2022.23.3.919","volume":"23","author":"L Khoshravan","year":"2022","unstructured":"Khoshravan L, Dadashpour M, Hashemi M, Zarghami N. Design and development of nanostructured Co delivery of Artemisinin and Chrysin for targeting hTERT gene expression in breast cancer cell line: possible clinical application in cancer treatment. Asian Pac J Cancer Prevention: APJCP. 2022;23(3):919\u201327.","journal-title":"Asian Pac J Cancer Prevention: APJCP"},{"issue":"1","key":"3259_CR18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10876-021-02217-y","volume":"34","author":"M Dadashpour","year":"2023","unstructured":"Dadashpour M, Ganjibakhsh M, Mousazadeh H, Nejati K. Increased Pro-Apoptotic and Anti-Proliferative activities of Simvastatin encapsulated PCL-PEG nanoparticles on human breast cancer adenocarcinoma cells. J Cluster Sci. 2023;34(1):211\u201322.","journal-title":"J Cluster Sci"},{"issue":"1","key":"3259_CR19","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12935-022-02605-y","volume":"22","author":"M Sharifi-Azad","year":"2022","unstructured":"Sharifi-Azad M, Fathi M, Cho WC, Barzegari A, Dadashi H, Dadashpour M, et al. Recent advances in targeted drug delivery systems for resistant colorectal cancer. Cancer Cell Int. 2022;22(1):196.","journal-title":"Cancer Cell Int"},{"issue":"2","key":"3259_CR20","doi-asserted-by":"publisher","first-page":"e12022","DOI":"10.1002\/bmm2.12022","volume":"1","author":"Z Tu","year":"2023","unstructured":"Tu Z, Timashev P, Chen J, Liang XJ. Ferritin-based drug delivery system for tumor therapy. BMEMat. 2023;1(2):e12022.","journal-title":"BMEMat"},{"issue":"3","key":"3259_CR21","doi-asserted-by":"publisher","first-page":"310","DOI":"10.4103\/0377-4929.188145","volume":"59","author":"A Pande","year":"2016","unstructured":"Pande A, Dorwal P, Jain D, Tyagi N, Mehra S, Sachdev R, et al. Expression of CD71 by flow cytometry in acute leukemias: more often seen in acute myeloid leukemia. Indian J Pathol Microbiol. 2016;59(3):310\u20133.","journal-title":"Indian J Pathol Microbiol"},{"key":"3259_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jconrel.2018.02.042","volume":"282","author":"M Khoshnejad","year":"2018","unstructured":"Khoshnejad M, Parhiz H, Shuvaev VV, Dmochowski IJ, Muzykantov VR. Ferritin-based drug delivery systems: hybrid nanocarriers for vascular immunotargeting. J Controlled Release: Official J Controlled Release Soc. 2018;282:13\u201324.","journal-title":"J Controlled Release: Official J Controlled Release Soc"},{"issue":"10","key":"3259_CR23","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1038\/s12276-022-00859-0","volume":"54","author":"NK Lee","year":"2022","unstructured":"Lee NK, Cho S, Kim I-S. Ferritin\u2013a multifaceted protein scaffold for biotherapeutics. Exp Mol Med. 2022;54(10):1652\u20137.","journal-title":"Exp Mol Med"},{"key":"3259_CR24","first-page":"149","volume-title":"Effective delivery of anti-PD-L1 SiRNA with human heavy chain ferritin (HFn) in acute myeloid leukemia cell lines","author":"M Rajabinejad","year":"2024","unstructured":"Rajabinejad M, Valadan R, Tehrani M, Najafi A, Negarandeh R, Saeedi M, et al. Effective delivery of anti-PD-L1 SiRNA with human heavy chain ferritin (HFn) in acute myeloid leukemia cell lines. Volume 41. London, England: Medical oncology (Northwood; 2024. p. 149. 6."},{"issue":"11","key":"3259_CR25","doi-asserted-by":"publisher","first-page":"e4792","DOI":"10.1002\/pro.4792","volume":"32","author":"EC Meng","year":"2023","unstructured":"Meng EC, Goddard TD, Pettersen EF, Couch GS, Pearson ZJ, Morris JH, et al. UCSF chimerax: tools for structure Building and analysis. Protein Science: Publication Protein Soc. 2023;32(11):e4792.","journal-title":"Protein Science: Publication Protein Soc"},{"issue":"2","key":"3259_CR26","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott O, Olson AJ. AutoDock vina: improving the speed and accuracy of Docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455\u201361.","journal-title":"J Comput Chem"},{"issue":"17","key":"3259_CR27","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.21037\/atm-21-3368","volume":"9","author":"J Wei","year":"2021","unstructured":"Wei J, Nai GY, Dai Y, Huang XJ, Xiong MY, Yao XY, et al. Dipetidyl peptidase-4 and transferrin receptor serve as prognostic biomarkers for acute myeloid leukemia. Annals Translational Med. 2021;9(17):1381.","journal-title":"Annals Translational Med"},{"issue":"10","key":"3259_CR28","doi-asserted-by":"publisher","first-page":"11570","DOI":"10.1002\/cam4.5778","volume":"12","author":"G Deng","year":"2023","unstructured":"Deng G, Li Y, Liang N, Hu P, Zhang Y, Qiao L, et al. Ferritin in cancer therapy: A pleiotropic Tumoraffin nanocage-based transport. Cancer Med. 2023;12(10):11570\u201388.","journal-title":"Cancer Med"},{"issue":"1","key":"3259_CR29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13046-021-01851-8","volume":"40","author":"E Falvo","year":"2021","unstructured":"Falvo E, Damiani V, Conti G, Boschi F, Messana K, Giacomini P, et al. High activity and low toxicity of a novel CD71-targeting nanotherapeutic named The-0504 on preclinical models of several human aggressive tumors. J Experimental Clin Cancer Research: CR. 2021;40(1):63.","journal-title":"J Experimental Clin Cancer Research: CR"},{"key":"3259_CR30","doi-asserted-by":"crossref","unstructured":"Markopoulos GS, Simos YV, Tsamis KI, Gartzonika K, Peschos D, Lakkas L. Beyond iron: the roles of CD71 in the pathophysiology of Cancer-A comprehensive review. J Clin Med. 2025;14(23):8295.","DOI":"10.3390\/jcm14238265"},{"issue":"8","key":"3259_CR31","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1158\/1535-7163.MCT-23-0548","volume":"23","author":"M Bratti","year":"2024","unstructured":"Bratti M, Stubbs E, Kolodych S, Souchet H, Kelly L, Merlin J, et al. INA03: A potent Transferrin-Competitive Antibody-Drug conjugate against CD71 for safer acute leukemia treatment. Mol Cancer Ther. 2024;23(8):1159\u201375.","journal-title":"Mol Cancer Ther"},{"key":"3259_CR32","doi-asserted-by":"crossref","unstructured":"Lucignano R, Ferraro G. Bioactive molecules delivery through ferritin nanoparticles: sum up of current loading methods. Molecules. 2024;29(17):4045.","DOI":"10.3390\/molecules29174045"},{"issue":"12","key":"3259_CR33","doi-asserted-by":"publisher","first-page":"e4819","DOI":"10.1002\/pro.4819","volume":"32","author":"A Incocciati","year":"2023","unstructured":"Incocciati A, Kube\u0161 J, Piacentini R, Cappelletti C, Botta S, Bertuccini L, et al. Hydrophobicity-enhanced ferritin nanoparticles for efficient encapsulation and targeted delivery of hydrophobic drugs to tumor cells. Protein Science: Publication Protein Soc. 2023;32(12):e4819.","journal-title":"Protein Science: Publication Protein Soc"},{"issue":"6","key":"3259_CR34","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1007\/s10565-023-09804-x","volume":"39","author":"J Jia","year":"2023","unstructured":"Jia J, Li M, Li Y, Xiao J, Dai H. The mtDNA-STING pathway plays an important role in both navitoclax- and S63845-induced autophagy and enhances cell death. Cell Biol Toxicol. 2023;39(6):2821\u201339.","journal-title":"Cell Biol Toxicol"},{"key":"3259_CR35","doi-asserted-by":"crossref","unstructured":"Waanders L, van der Donk LEH, Ates LS, Maaskant J, van Hamme JL, Eldering E et al. Ectopic expression of cGAS in Salmonella typhimurium enhances STING-mediated IFN-\u03b2 response in human macrophages and dendritic cells. J Immunother Cancer. 2023;11(4):e005839.","DOI":"10.1136\/jitc-2022-005839"},{"key":"3259_CR36","doi-asserted-by":"publisher","first-page":"1295208","DOI":"10.3389\/fimmu.2023.1295208","volume":"14","author":"GM Rodriguez","year":"2023","unstructured":"Rodriguez GM, Yakubovich E, Murshed H, Maranda V, Galpin KJC, Cudmore A, et al. NLRC5 overexpression in ovarian tumors remodels the tumor microenvironment and increases T-cell reactivity toward autologous tumor-associated antigens. Front Immunol. 2023;14:1295208.","journal-title":"Front Immunol"},{"key":"3259_CR37","doi-asserted-by":"publisher","first-page":"1476030","DOI":"10.3389\/fimmu.2024.1476030","volume":"15","author":"Y Cao","year":"2024","unstructured":"Cao Y, Yi Y, Han C, Shi B. NF-\u03baB signaling pathway in tumor microenvironment. Front Immunol. 2024;15:1476030.","journal-title":"Front Immunol"},{"issue":"42","key":"3259_CR38","first-page":"e2403409","volume":"20","author":"X Wu","year":"2024","unstructured":"Wu X, Wang F, Yang X, Gong Y, Niu T, Chu B, et al. Advances in drug delivery systems for the treatment of acute myeloid Leukemia. Small (Weinheim an der Bergstrasse. Germany). 2024;20(42):e2403409.","journal-title":"Germany)"},{"key":"3259_CR39","doi-asserted-by":"crossref","unstructured":"Zhao J, Cui J, Wang L, Shi X, Ding J, Sohail MF et al. Nanomaterials for acute myeloid leukemia therapy: current progress and future perspectives. Interdisciplinary Med. 2025;3(3):e20240131.","DOI":"10.1002\/INMD.20240131"},{"issue":"9","key":"3259_CR40","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1021\/acs.molpharmaceut.8b00277","volume":"15","author":"G Kibria","year":"2018","unstructured":"Kibria G, Ramos EK, Wan Y, Gius DR, Liu H. Exosomes as a drug delivery system in cancer therapy: potential and challenges. Mol Pharm. 2018;15(9):3625\u201333.","journal-title":"Mol Pharm"},{"issue":"5","key":"3259_CR41","doi-asserted-by":"publisher","first-page":"e13807","DOI":"10.1111\/cts.13807","volume":"17","author":"AH Salem","year":"2024","unstructured":"Salem AH, Menon RM. Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B-cell lymphoma-2 inhibitor. Clin Transl Sci. 2024;17(5):e13807.","journal-title":"Clin Transl Sci"},{"key":"3259_CR42","doi-asserted-by":"publisher","first-page":"116165","DOI":"10.1016\/j.foodres.2025.116165","volume":"209","author":"L He","year":"2025","unstructured":"He L, Zhang L, Meng F, Wei J, Chen F, Qin S, et al. Dietary emulsifier polysorbate 80-induced lipotoxicity promotes intestinal senescence. Food Res Int. 2025;209:116165.","journal-title":"Food Res Int"},{"key":"3259_CR43","doi-asserted-by":"crossref","unstructured":"Totiger TM, Ghoshal A, Zabroski J, Sondhi A, Bucha S, Jahn J et al. Targeted therapy development in acute myeloid leukemia. Biomedicines. 2023;11(2):641.","DOI":"10.3390\/biomedicines11020641"},{"issue":"6","key":"3259_CR44","doi-asserted-by":"publisher","first-page":"e2016","DOI":"10.1002\/wnan.2016","volume":"16","author":"A Macone","year":"2024","unstructured":"Macone A, Cappelletti C, Incocciati A, Piacentini R, Botta S, Boffi A, et al. Challenges in exploiting human H ferritin nanoparticles for drug delivery: navigating physiological constraints. Wiley Interdisciplinary Reviews Nanomed Nanobiotechnol. 2024;16(6):e2016.","journal-title":"Wiley Interdisciplinary Reviews Nanomed Nanobiotechnol"},{"key":"3259_CR45","doi-asserted-by":"crossref","unstructured":"Zheng K, Song R, Li R, Liu M, Ba Y, Jiang W, et al. Nanomaterials for refining tumor microenvironment and enhancing therapy in head and neck squamous cell carcinoma: a review. Oncology and Translational Medicine; 2024.","DOI":"10.1097\/ot9.0000000000000046"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03259-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03259-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03259-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T12:04:15Z","timestamp":1775649855000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03259-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":45,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["3259"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03259-w","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"28 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"132"}}